<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5251-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACIDOXAX 4MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        57.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Actavis Italy SpA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Actavis Italy SpA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Acidoxax is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:</p><p>To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).<br />To reduce the amount of calcium&nbsp;in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all instructions given to you by your doctor.</p><p>Your doctor will carry out blood tests before you start treatment with Acidoxax and will check your response to treatment at regular intervals.</p><p>You should not be given Acidoxax:</p><p>- if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which Acidoxax belongs), or any of the other ingredients of this medicine (listed in section 6).</p><p>- if you are breast-feeding.</p><p>Warnings and precautions</p><p>Talk to your doctor before you are given Acidoxax:</p><p>&nbsp;</p><p>if you have or have had a&nbsp;kidney problem.<br />if you have or have had&nbsp;pain, swelling or numbness&nbsp;of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. Your doctor may recommend a dental examination before you start treatment with Acidoxax.<br />if you are having&nbsp;dental treatment&nbsp;or are due to undergo dental surgery, tell your dentist that you are being treated with Acidoxax and inform your doctor about your dental treatment.</p><p>While being treated with&nbsp;Acidoxax, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.</p><p>Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw.</p><p>Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.</p><p>Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with zoledronic acid. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. In some instances the hypocalcaemia may be life-threatening. If any of these apply to you, tell your doctor straight away. If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Acidoxax. You will be given adequate calcium and vitamin D supplements.</p><p>Patients aged 65 years and over</p><p>Acidoxax can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.</p><p>Children and adolescents</p><p>Acidoxax is not recommended for use in adolescents and children below the age of 18 years.</p><p>Other medicines and Acidoxax</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. It is especially important that you tell your doctor if you are also taking:</p><ul><li><p>- &nbsp;Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to</p><p>treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low.</p></li><li><p>- &nbsp;Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.</p></li><li><p>- &nbsp;Other medicines that contain zoledronic acid which are used to treat osteoporosis and other non- cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Acidoxax are unknown.</p></li><li><p>- &nbsp;Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).</p></li></ul><p>Pregnancy and breast-feeding</p><p>You should not be given Acidoxax if you are pregnant. Tell your doctor if you are or think that you may be pregnant.</p><p>You must not be given Acidoxax if you are breast-feeding.</p><p>Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.</p><p>Driving and using machines</p><p>There have been very rare cases of drowsiness and sleepiness with the use of zoledronic acid. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.</p><p>Acidoxax contains sodium</p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per dose, i.e. it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;Acidoxax must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.</p><ul><li><p>- &nbsp;Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.</p></li><li><p>- &nbsp;Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.</p><p>How much Acidoxax is given</p><p>- The usual single dose given is 4 mg.<br />- If you have a kidney problem, your doctor will give you a lower dose depending on the severity of</p><p>your kidney problem.</p><p>How often Acidoxax is given</p></li></ul><ul><li><p>- &nbsp;If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Acidoxax every three to four weeks.</p></li><li><p>- &nbsp;If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Acidoxax.</p><p>How Acidoxax is given</p></li></ul><p>- Acidoxax is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.</p><p>Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.</p><p>If you are given more Acidoxax than you should be</p><p>If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.</p><p>Tell your doctor about any of the following serious side effects straight away:</p><p>Common&nbsp;(may affect up to 1 in 10 people):<br />- Severe kidney impairment (will normally be determined by your doctor with certain specific blood</p><p>tests).<br />- Low level of calcium in the blood.</p><p>Uncommon&nbsp;(may affect up to 1 in 100 people):</p><ul><li><p>- &nbsp;Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw,</p><p>discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with Acidoxax or after stopping treatment.</p></li><li><p>- &nbsp;Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.</p></li><li><p>- &nbsp;Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.</p><p>Rare&nbsp;(may affect up to 1 in 1,000 people):</p></li></ul><p>- As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to</p><p>hypocalcaemia).</p><p>Very rare&nbsp;(may affect up to 1 in 10,000 people):</p><ul><li><p>- &nbsp;As a consequence of low calcium values: seizures, numbness and tetany (secondary to</p><p>hypocalcaemia).</p></li><li><p>- &nbsp;Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could</p><p>be signs of bone damage in the ear.</p><p>Tell your doctor about any of the following side effects as soon as possible: Very common&nbsp;(may affect more than 1 in 10 people):</p></li></ul><p>- Low level of phosphate in the blood.&nbsp;Common&nbsp;(may affect up to 1 in 10 people):</p><p>-</p><p>- - -</p><p>Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days).</p><p>Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite. Conjunctivitis.</p><p>Low level of red blood cells (anaemia).</p><p>Uncommon&nbsp;(may affect up to 1 in 100 people):</p><p>- - - - -</p><p>- -</p><p>- - - - - - -</p><p>Hypersensitivity reactions.<br />Low blood pressure.<br />Chest pain.<br />Skin reactions (redness and swelling) at the infusion site, rash, itching.</p><p>High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhoea, constipation, abdominal pain, dry mouth.</p><p>Low counts of white blood cells and blood platelets.<br />Low level of magnesium and potassium in the blood. Your doctor will monitor this and take any necessary measures.<br />Weight increase.<br />Increased sweating.</p><p>Sleepiness.<br />Blurred vision, tearing of the eye, eye sensitivity to light. Sudden coldness with fainting, limpness or collapse. Difficulty in breathing with wheezing or coughing. Urticaria.</p><p>Rare&nbsp;(may affect up to 1 in 1,000 people):</p><p>- - -</p><p>- - -</p><p>Slow heart beat.</p><p>Confusion.<br />Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone. Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)<br />Flu-like symptoms including arthritis and joint swelling.<br />Painful redness and/or swelling of the eye.</p><p>Very rare (may affect up to 1 in 10,000 people):</p><ul><li><p>- &nbsp;Fainting due to low blood pressure.</p></li><li><p>- &nbsp;Severe bone, joint and/or muscle pain, occasionally incapacitating.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E-mail: npc.drug@sfda.gov.sa. By reporting side effects you can help provide more information on the safety of this medicine.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor, pharmacist or nurse knows how to store Acidoxax properly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Acidoxax contains</p><ul><li><p>- &nbsp;The active substance is zoledronic acid. One vial contains 4 mg zoledronic acid (as monohydrate).</p></li><li><p>- &nbsp;The other ingredients are: mannitol, sodium citrate and water for injections.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Acidoxax is supplied as a clear and colourless concentrate for solution for infusion (sterile concentrate) in a plastic vial. One vial contains 5 ml of solution.
Acidoxax is supplied as packs containing 1, 4 or 10 vials. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li><p>Marketing Authorisation Holder</p><p>Tadawi Biomedical company Olaya st<br />Riyadh, Saudia Arabia</p><p>Manufacturer</p><p>Actavis Italy S.p.A. Via Pasteur 10 20014 Nerviano (MI) Italy</p></li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 06/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">إن المادة الفعالة الموجودة في أسيدوكساكس هي حمض زوليدرونيك, وهي تعود لمجموعة من المواد التي تدعى بيسفوسفونايتس.حيث يعمل حمض الزوليدرونيك بربط نفسه بالعظم وإبطاء سرعة تغير العظم، وهو يستعمل:</p><p dir="RTL">-&nbsp;<strong>لمنع حدوث إشكالات في العظم</strong>, مثل الكسور في المرضى الكبار المصابين&nbsp;&nbsp;بحالات من النمو الثانوي لورم خبيث في العظم (إنتشار السرطان من موقع أولي للعظم).</p><p dir="RTL">-&nbsp;<strong>لتقليل كمية الكالسيوم</strong>&nbsp;في الدم لدى المرضى الكبار حيث تكون عالية جداً بسبب وجود ورم ما. ويمكن للأورام أن تسرع التغير الطبيعي للعظم&nbsp;&nbsp;بطريقة يمكن بها أن يزداد إطلاق الكالسيوم من العظم. وتعرف هذه الحالة بفرط سكر الدم الناتج عن إنبثاث الورم&nbsp;(TIH).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">اتبع بكل عناية جميع التعليمات المقدمة إليك من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يجري طبيبك تحاليل للدم قبل أن تبدأ المعالجة بأسيدوكساكس وسوف يتحقق من إستجابتك للمعالجة على فترات زمنية دورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عدم إعطائك أسيدوكساكس:</strong></p><p dir="RTL">- إذا كنت تتحسس من حمض الزوليدرونيك أو من بيسفوسفونايت آخر (مجموعة المواد التي ينتمي إليها أسيدوكساكس), أو أية مواد أخرى لهذا الدواء (مدرجة في البند 6).</p><p dir="RTL">- إذا كنتِ مُرضعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إنذارات وتحذيرات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدّث إلى طبيبك قبل إعطائك أسيدوكساكس</strong></p><p dir="RTL">- إذا كانت لديك أو سبق أن كانت لديك&nbsp;<strong>مشكلة كلوية</strong>.</p><p dir="RTL">- إذا كان لديك أو سبق أن كان لديك&nbsp;<strong>ألم</strong>&nbsp;أو&nbsp;<strong>تورم</strong>&nbsp;أو&nbsp;<strong>خدر</strong>&nbsp;في الفك, وشعور بثقل في الفك أو خلخلة بأحد الأسنان. ما يمكن لطبيبك أن يشير عليك بإجراء فحص الأسنان قبل أن تبدأ بالمعالجة بأسيدوكساكس.</p><p dir="RTL">- إذا كنت تقوم&nbsp;<strong>بمعالجة سنية</strong>&nbsp;أو أنك تخضع لجراحة سنية, عليك أن تخبر طبيب أسنانك بأنك تعالج حالياً بأسيدوكساكس وأن تخبر طبيبك بشأن معالجتك السنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وبينما تقوم بالمعالجة بأسيدوكساكس, عليك أن تحافظ على صحتك الفموية (بما في ذلك الفرجنة الدورية للأسنان) وأن تجري فحوصاً سنية روتينية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إتصل بطبيبك وطبيب أسنانك فوراً إذا كنت تعاني من أية مشاكل بفمك أو بأسنانك مثل تخلخل الأسنان أو بألم أو تورم أو عدم شفاء الإلتهابات أو التدفق, لأن ذلك يمكن أن يكون علامات لحالة تدعى تنخر عظم الفك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن المرضى الذين يخضعون للمعالجة الكيميائية و/أو المعالجة الشعاعية, الذين يتناولون الستيروئيدات, والذين يخضعون للجراحة السنية, والذين لم يتلقوا العناية السنية الروتينية, والذين لديهم مرض اللثة,&nbsp;&nbsp;والمدخنين, أو الذين عولجوا في السابق بدواء بيسفوسفونايت (الذين اعتادوا أو كانوا يعملون على منع حدوث خلل في العظام)، إن هؤلاء يمكن أن تكون لديهم مخاطرة أكبر لحدوث تنخر في عظم الفك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نشر عن إنخفاض في مستويات الكالسيوم في الدم (نقص كلس الدم), الذي يؤدي أحياناً لتشنجات عضلية, أو تجفاف في الجلد, أو إحساس بالحرقة, لدى مرضى عولجوا بحمض الزوليدرونيك. كما نشر عن&nbsp;&nbsp;أن عدم إنتظام ضربات القلب (إيقاع غير منتظم للقلب), ونوبات, وتشنج وارتعاش (تكزز),&nbsp;&nbsp;إنما هو نقص ثانوي إلى نقص حاد في كلس الدم. في بعض الأحيان يمكن أن يشكل نقص كلس الدم تهديداً للحياة. فإذا كان أي من هؤلاء ينطبق على حالتكم, ينبغي عليكم أن تخبروا طبيبكم بذلك فوراً. وإذا كانت لديكم حالة مسبقة لنقص كلس الدم, ينبغي تصحيحها قبل المباشرة بالجرعة الأولى لأسيدوكساكس. حيث سيتم إعطاءكم متممات كافية من الكلس مع الفيتامين (د).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى من عمر 65 عاماً فما فوق</strong></p><p dir="RTL">يجوز إعطاء أسيدوكساكس للأشخاص الذين هم بعمر الـ 65 عاماً فما فوق. ولا يوجد هناك أي دليل يوحي بضرورة إتخاذ أية إحتياطات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح باستعمال أسيدوكساكس للمراهقين والأطفال دون سن الثامنة عشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وأسيدوكساكس</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ الآن, أو أنك أخذت مؤخراً أو أنك يمكن أن تأخذ أية أدوية أخرى. ومن المهم بشكل خاص أن تخبر طبيبك إذا كنت تأخذ الآن أيضاً:</p><p dir="RTL">- أمينوغليكوسيد (أدوية تستعمل لمعالجة عدوات شديدة)، كالسيتونين (نوع من الأدوية يستعمل لمعالجة هشاشة العظام بعد إنقطاع العادة الشهرية و نقص كلس الدم)، مدرات حلقية للبول (نوع من الأدوية لمعالجة ضغط الدم المرتفع أو الإستسقاء) أو أية أدوية أخرى خافضة للكالسيوم, لأن إتحاد هذه الأدوية مع بيسفوسفونايتس يمكن أن يسبب إنحفاضاً شديداً جداً لمستوى الكالسيوم في الدم.</p><p dir="RTL">- تاليدوميد (دواء يستعمل لمعالجة نوع محدد من سرطان الدم يصيب العظم) أو أية أدوية أخرى التي يمكن أن تؤذي الكليتين.</p><p dir="RTL">- أدوية أخرى تحتوي حمض الزوليدرونيك المستعملة لمعالجة هشاشة العظام وأمراض أخرى غير سرطانية للعظم, أو أية بيسفوسفونايت أخرى, ذلك أن التأثيرات الموحدة لهذه الأدوية التي تؤخذ سوية مع أسيدوكساكس هي غير معروفة.</p><p dir="RTL">- الأدوية المضادة لتكون الأوعية (المستعملة في معالجة السرطان), لأن إتحاد هذه الأدوية مع حمض الزوليدرونيك قد ارتبط مع خطورة متزايدة لتنخرعظم الفك&nbsp;(ONJ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">ينبغي عدم إعطائكِ أسيدوكساكس إذا كنت حاملاً. أخبري طبيبك إذا كنتِ حاملاً أو تفكرين بإمكانية الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم إعطائكِ أسيدوكساكس إذا كنت مرضعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إستشيري طبيبك قبل أن تأخذي أي دواء إذا كنتِ حاملاً أو مرضعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآلات</strong></p><p dir="RTL">وجدت حالات نادرة جداً للنعاس أو النوم باستعمال حمض الزوليدرونيك. لذلك يجب الإنتباه عند قيادة السيارة أو إستعمال الآلات أو القيام بأية أعمال أخرى تتطلب إنتباهاً كاملاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أسيدوكساكس يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول (23 ملغ) من الصوديوم بالجرعة الواحدة، أي أن من الضروري أن يكون &quot;خالياً من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">- يجب إعطاء هذا الدواء فقط من قبل محترفين بالعناية الصحية مدربين على إعطاء البيسفوسفونايتس وريدياً، أي عبر أحد الأوردة.</p><p dir="RTL">- سوف ينصحك طبيبك بشرب ماء كافٍ قبل أية معالجة للمساعدة في منع حدوث تجفاف.</p><p dir="RTL">- إتبع بعناية جميع التعليمات الأخرى المقدمة إليك من قبل طبيبك, أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كمية الأسيدوكساكس المعطاة</strong></p><p dir="RTL">- تبلغ الجرعة الفردية الإعتيادية 4 ملغ.</p><p dir="RTL">- إذا كنت تعاني من مشكلة كلوية, سوف يعطيك طبيبك جرعة أقل حسب شدة مشكلتك الكلوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يتم غالباً إعطاء أسيدوكساكس</strong></p><p dir="RTL">- إذا كنت تُعالج لمنع حدوث إشكالات عظمية بسبب نمو ثانوي لورم سرطاني في العظم, سوف تُعطى حقنة واحدة من الأسيدوكساكس كل ثلاثة إلى أربعة أسابيع.</p><p dir="RTL">- إذا كنت تُعالج لتخفيض كمية الكالسيوم في دمك, سوف تعطى بشكل طبيعي حقنة واحدة فقط من الأسيدوكساكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعطى أسيدوكساكس</strong></p><p dir="RTL">- يعطى أسيدوكساكس&nbsp;&nbsp;كالتنقيط (التسريب) في أحد الأوردة والتي يجب أن تستغرق 15 دقيقة على الأقل ويجب إعطاؤها كمحلول وريدي واحد بأنبوب حقن منفصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">والمرضى الذين تكون مستويات الكالسيوم في الدم لديهم ليست مرتفعة جداً سوف يوصف لهم أيضاً الكالسيوم مع الفيتامين (د) متممات لتؤخذ كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أعطيتَ أسيدوكساكس أكثر مما ينبغي</strong></p><p dir="RTL">إذا تلقيت جرعات أعلى من الجرعات الموصوفة, ينبغي أن تُراقب بعناية من قبل طبيبك. ذلك أنه يمكن أن تحدث لك حالات شاذة من إلكتروليت المصل (مثل مستويات غير طبيعية من الكالسيوم, والفوسفور والمغنيزيوم) و/أو تغيرات في وظيفة الكليتين, بما في ذلك إعتلال شديد في الكليتين. وإذا انخفض مستوى الكالسيوم لديك كثيراً جداً, ربما يترتب عليك أن تُعطى الكالسيوم متمماً بالتسريب.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن هذا الدواء مثل جميع الأدوية الأخرى, يمكن أن يسبب تأثيرات جانبية, وإن كانت لا تحدث لكل شخص. وإن التأثيرات الجانبية الأكثر شيوعاً عادةً ما تكون خفيفة ومن المحتمل أن تزول بعد فترة قصيرة من الزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك فوراً عن أي من التأثيرات الجانبية الخطيرة التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة</strong>&nbsp;(يمكن أن تصيب 1 من 10 من الأشخاص):</p><p dir="RTL">- إعتلال كلوي شديد (يتم تحديده بشكل طبيعي من قبل طبيبك إلى جانب إجراء بعض التحاليل الخاصة للدم).</p><p dir="RTL">- مستوى منخفض للكالسيوم في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة</strong>&nbsp;(يمكن أن تصيب 1 من 100 من الأشخاص):</p><p dir="RTL">- ألم في الفم, الأسنان و/&nbsp;أو الفك, تورم أو عدم إستشفاء للإلتهابات داخل الفم أو الفك, أو تدفق أو خدر أو شعور بثقل في الفك, أو خلخلة في أحد الأسنان. وهذه يمكن أن تكون علامات عن وجود تلف عظمي في الفك&nbsp;&nbsp;(تنخر عظمي). أخبر طبيبك وطبيب أسنانك فوراً إذا كنت تعاني من مثل هذه الأعراض بينما أنت تُعالج&nbsp;&nbsp;بالأسيدوكساكس أو بعد توقيف المعالجة.</p><p dir="RTL">- شوهد إنتظام غير طبيعي في القلب (رجفان أذيني) لدى مرضى يتلقون حمض الزوليدرونيك لهشاشة العظام بعد توقف العادة الشهرية. ومن غير الواضح حالياً ما إذا كان حمض الزوليدرونيك يسبب عدم الإنتظام غير الطبيعي للقلب, ولكن عليك أن تخبر طبيبك إذا كنت تعاني من هذه الأعراض بعد تناولك حمض الزوليدرونيك.</p><p dir="RTL">- رد فعل تحسسي شديد: ضيق بالتنفس, وتورم بشكل رئيسي في الوجه والحلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة</strong>&nbsp;(يمكن أن تصيب 1 من 1000 من الأشخاص):</p><p dir="RTL">- نتيجة لانخفاض معدلات الكالسيوم: عدم إنتظام ضربات القلب (عدم إنتظام ضربات القلب ناتج عن نقص الكلس في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة جداً (يمكن أن تصيب 1 من 10,000 من الأشخاص):</strong></p><p dir="RTL">-&nbsp;نتيجة لانخفاض معدلات الكالسيوم: نوبات، وخدر وكزاز (ناتج عن عدم إنتظام ضربات القلب لاحقة نقص الكلس في الدم).</p><p dir="RTL">- تحدّث إلى طبيبك إذا كنت تشعر بألم في الأذن, أو سيلان من الأذن, و/أو عدوى في الأذن. ذلك أن هذه الأمور يمكن أن تكون علامات لتلف في عظم الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك بشأن أي من التأثيرات الجانبية التالية بالسرعة الممكنة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة جداً</strong>&nbsp;(يمكن أن تصيب أكثر من 1 / 10 من الأشخاص) :</p><p dir="RTL">- مستوى منخفض للفوسفات في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة</strong>&nbsp;(يمكن أن تصيب&nbsp;&nbsp;1 من 10 من الأشخاص) :</p><p dir="RTL">- وجع رأس ومتلازمة شبيهة الأنفلونزا وتتألف من حمى, وتعب, وضعف, ونعاس, وبردية وألم بالعظم, وألم بالمفاصل و/&nbsp;أو بالعضلات. وفي أغلب الحالات لا يحتاج الأمر لأية معالجة خاصة وتزول الأعراض بعد فترة قصيرة من الزمن (ساعتان أو يومان).</p><p dir="RTL">- ردود فعل معدية ومعوية مثل الغثيان والتقيؤ وكذلك إنعدام الشهية.</p><p dir="RTL">- إلتهاب الملتحمة.</p><p dir="RTL">- مستوى منخفض لخلايا الدم الحمراء (فقر دم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة</strong>&nbsp;(تصيب 1 من 100 من الأشخاص) :</p><p dir="RTL">- ردود فعل عالية الحساسية.</p><p dir="RTL">- ضغط دم منخفض.</p><p dir="RTL">- ألم في الصدر.</p><p dir="RTL">- ردود فعل جلدية (إحمرار وتورم) في موقع الحقن, وطفح, وحكة.</p><p dir="RTL">- ضغط دم مرتفع، ضيق تنفس، دوخة، قلق، إضطرابات في النوم، إضطرابات في التذوق، رجفان، تنميل أو خدر في اليدين أو القدمين، إسهال، إمساك، ألم في البطن، جفاف الفم.</p><p dir="RTL">- إنخفاض عدد الكريات البيض والصفائح الدموية.</p><p dir="RTL">- إنخفاض مستوى المغنيزيوم والبوتاسيوم في الدم. وسوف يراقب طبيبك هذا الوضع ويتخذ أية تدابير ضرورية.</p><p dir="RTL">- زيادة في الوزن.</p><p dir="RTL">- زيادة في التعرق.</p><p dir="RTL">- نُوام.</p><p dir="RTL">- زوغان في الرؤية، دمعان في العينين، حساسية العينين للضوء.</p><p dir="RTL">- برودة مفاجئة مع إغماء, أو ترهل أو إنهيار.</p><p dir="RTL">- صعوبة في التنفس إلى جانب لهاث أو سعال.</p><p dir="RTL">- طفح جلدي مع بثور (الشرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة</strong>&nbsp;(تصيب 1 من 1000 من الأشخاص) :</p><p dir="RTL">- ضربات بطيئة للقلب.</p><p dir="RTL">- إرتباك.</p><p dir="RTL">- كسر غير عادي لعظم الفخذ نادراً ما يحدث خاصة لدى المرضى الذين يعالجون معالجة طويلة الأمد لأجل هشاشة العظام. فعليك أن تتصل بطبيبك إذا كنت تعاني من ألم, ضعف أو عدم إرتياح في فخذك, وركك أو أريبة أصل الفخذ, لأن هذا ربما يكون إشارة مبكرة لكسر محتمل في عظم الفخذ.</p><p dir="RTL">- مرض بين فرجي الرئتين (التهاب النسيج المحيط بالأكياس الهوائية للرئتين).</p><p dir="RTL">- أعراض شبيهة الأنفلونزا بما في ذلك إلتهاب وتورم المفاصل.</p><p dir="RTL">- إحمرار مؤلم و/أو تورم العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة جداً</strong>&nbsp;(تصيب 1 من 10,000 من الأشخاص) :</p><p dir="RTL">- إغماء ناتج عن إنخفاض ضغط الدم.</p><p dir="RTL">- ألم شديد في العظم والمفاصل و/&nbsp;أو ألم في العضلات وأحياناً العجز.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية&nbsp;</strong></p><p dir="RTL">إذا حدثت لك أية تأثيرات جانبية, تحدّث إلى طبيبك, أو إلى الصيدلي أو إلى الممرضة. ويشمل ذلك أية تأثيرات جانبية محتملة غير مدرجة في هذه النشرة. ويمكنك أيضاً أن تبلغ عن التأثيرات الجانبية مباشرة عن طريق المركز الوطني لليقظة الصيدلانية وسلامة الأدوية&nbsp;(NPC):</p><p dir="RTL">هاتف:&nbsp;&nbsp;+966-11-2038222,&nbsp;&nbsp;&nbsp;Exts: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">ويمكنك الإتصال مجاناً على الهاتف:&nbsp;&nbsp;80022490000</p><p dir="RTL">وبالبريد الإلكتروني:&nbsp;npe.drug@sfda.gov.sa</p><p dir="RTL">وبالإبلاغ عن التأثيرات الجانبية يمكنك أن تساعد في إعطاء المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يعرف طبيبك, أو الصيدلي أو ممرضتك كيف يحفظ هذا الدواء بشكل صحيح.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي حمض الزوليدرونيك. وتحتوي القارورة الواحدة على 4 ملغ من حمض الزوليدرونيك (بشكل مونوهايدرات).</p><p dir="RTL">- المواد الأخرى هي: مانيتول، سيترات الصوديوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم توريد الأسيدوكساكس كمركب رائق عديم اللون للحل من أجل الحقن (مركب معقم) في قارورة بلاستيكية. وتحتوي القارورة الواحدة على 5 مل من المحلول.</p><p dir="RTL">يتم توريد أسيدوكساكس بعلب تحتوي على قارورة واحدة أو أربع قارورات أو عشر قارورات. وليست جميع العبوات يمكن تسويقها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>تداوي الحيوية الطبية</p><p>&nbsp;</p><p>مدينة سدير الصناعية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            6/2016.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acidoxax4 mg/5 ml concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate). One ml concentrate contains 0.8 mg zoledronic acid (as monohydrate).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Concentrate for solution for infusion (sterile concentrate). Clear and colourless concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li><p>- &nbsp;Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.</p></li><li><p>- &nbsp;Treatment of adult patients with tumour-induced hypercalcaemia (TIH).</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acidoxaxmust only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with Acidoxaxshould be given the package leaflet and the patient reminder card.</p><p>Posology</p><p>Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and older people<br />The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks.</p><p>Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p>Treatment of TIH<br />Adults and older people<br />The recommended dose in hypercalcaemia (albumin-corrected serum calcium&nbsp;&ge;&nbsp;12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid.</p><p><img alt="page2image65698624" width="40.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5f736586-ef37-4912-8cb8-154d5cebee60" />&nbsp;<img alt="page2image65698240" width="407.830000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7a1c0669-3c70-4f15-93e9-ac4945aac971" />&nbsp;<img alt="page2image65699392" width="77.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/57bc87ec-1939-438c-b084-f188c0d2befa" /></p><p>2</p><p>Renal impairment<br />TIH:<br />Acidoxaxtreatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine &gt; 400 micromol/l or &gt; 4.5 mg/dl were excluded. No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 micromol/l or &lt; 4.5 mg/dl (see section 4.4).</p><p>Prevention of skeletal related events in patients with advanced malignancies involving bone:</p><p>When initiating treatment with Acidoxaxin patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine using the Cockcroft-Gault formula. Acidoxaxis not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr &lt; 30 ml/min. In clinical trials with zoledronic acid, patients with serum creatinine &gt; 265 micromol/l or &gt; 3.0 mg/dl were excluded.</p><p>In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, the following Acidoxaxdose is recommended (see also section 4.4):</p><p><img alt="page3image65674560" width="79.560000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/d41be417-7607-42f4-9173-71e386a9c135" /></p><p>Baseline Creatinine Clearance (ml/min)</p><p>&gt; 60 50-60 40-49 30-39</p><p>Acidoxaxrecommended dose*</p><p>4.0 mg zoledronic acid 3.5 mg* zoledronic acid 3.3 mg* zoledronic acid 3.0 mg* zoledronic acid</p><p><img alt="page3image65680704" width="232.250000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/dfe6ba8a-ef7a-422d-a06f-aa2dd0915b9b" />&nbsp;<img alt="page3image65673984" width="231.770000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/25af7e33-74a1-4808-8851-b68cdeb46cb3" />&nbsp;<img alt="page3image65672640" width="232.970000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/33ebbad6-116c-428b-8448-fdff1413e8c3" /><img alt="page3image65681088" width="232.490000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3ddcd3c1-444d-4489-883e-48ca76dad393" /></p><p>*&nbsp;Doses have been calculated assuming target AUC of 0.66&nbsp;(mg&bull;hr/l) (CLcr&nbsp;= 75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.</p><p>Following initiation of therapy, serum creatinine should be measured prior to each dose of Acidoxaxand treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:<br />- For patients with normal baseline serum creatinine (&lt; 1.4 mg/dl or &lt; 124 micromol/l), an</p><p>increase of 0.5 mg/dl or 44 micromol/l;<br />- For patients with abnormal baseline creatinine (&gt; 1.4 mg/dl or &gt; 124 micromol/l), an increase</p><p>of 1.0 mg/dl or 88 micromol/l.</p><p>In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4). Acidoxaxtreatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>Paediatric population</p><p>The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>Method of administration<br />Intravenous use.<br />Acidoxax4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.</p><p>In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended&nbsp;(see section &ldquo;Posology&rdquo; above and section&nbsp;4.4).</p><p><img alt="page3image65667648" width="97.584000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/07f213ad-ebf9-4c01-b7e6-2937c0e27095" />&nbsp;<img alt="page3image65668608" width="113.180000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c3d57c2d-4ed8-4e88-849a-cf8294720daf" /></p><p>3</p><p>Instructions for preparing reduced doses of Zoledronic acid Actavis Withdraw an appropriate volume of the concentrate needed, as follows:</p><ul><li><p>- &nbsp;4.4 ml for 3.5 mg dose</p></li><li><p>- &nbsp;4.1 ml for 3.3 mg dose</p></li><li><p>- &nbsp;3.8 ml for 3.0 mg dose</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6. The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. The dose must be given as a single intravenous infusion over no less than 15 minutes.</p><p>Acidoxaxmust not be mixed with calcium or other divalent cation-containing infusion solutions such&nbsp;as lactated Ringer&rsquo;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p><p>Patients must be maintained well hydrated prior to and following administration of Zoledronic acid Actavis.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
• Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1
• Breast-feeding (see section 4.6)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Patients must be assessed prior to administration of Acidoxaxto ensure that they are adequately hydrated.</p><p>Overhydration should be avoided in patients at risk of cardiac failure.</p><p>Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating Acidoxaxtherapy. If hypocalcaemia, hypophosphataemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.</p><p>Other products containing zoledronic acid as active substances are available for osteoporosis indications and treatment of Paget ́s disease of the bone. Patients being treated with Acidoxaxshould not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.</p><p>Renal insufficiency<br />Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Acidoxaxoutweighs the possible risk.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p>Zoledronic acid, used as indicated in sections 4.1 and 4.2, has been associated with reports of renal dysfunction. Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid and other bisphosphonates as well as use of other nephrotoxic medicinal products. While the risk is reduced with a dose of 4 mg zoledronic acid administered over 15 minutes, deterioration in renal function may</p><p><img alt="page4image66013632" width="299.210000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/f67afdd1-3ab7-44e8-a746-2c8549e1b194" />&nbsp;<img alt="page4image66019968" width="35.040000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1ce5e0ea-d0ee-4ce7-b52a-05d7f95d6de0" />&nbsp;<img alt="page4image66025152" width="86.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ee423c12-0cf2-428e-b497-265867713d52" /></p><p>4</p><p>still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently.</p><p>Patients should have their serum creatinine levels assessed prior to each dose of Zoledronic acid Actavis. Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of zoledronic acid are recommended. In patients who show evidence of renal deterioration during treatment, Acidoxaxshould be withheld. Acidoxaxshould only be resumed when serum creatinine returns to within 10% of baseline. Acidoxaxtreatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine&nbsp;&ge;&nbsp;400 micromol/l or&nbsp;&ge;&nbsp;4.5 mg/dl for patients with TIH and&nbsp;&ge;&nbsp;265 micromol/l or&nbsp;&ge;&nbsp;3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance &lt; 30 ml/min), the use of Acidoxaxis not recommended in patients with severe renal impairment.</p><p>Hepatic insufficiency<br />As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.</p><p>Osteonecrosis of the jaw<br />Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post-marketing setting in patients receiving zoledronic acid.</p><p>The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth, except in medical emergency situations. A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphosphonates in patients with concomitant risk factors.</p><p>The following risk factors should be considered when evaluating an individual&rsquo;s risk of developing&nbsp;ONJ:</p><ul><li><p>- &nbsp;Potency of the bisphosphonate (higher risk for highly potent compounds), route of</p><p>administration (higher risk for parenteral administration) and cumulative dose of</p><p>bisphosphonate.</p></li><li><p>- &nbsp;Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</p></li><li><p>- &nbsp;Concomitant therapies: chemotherapy, angiogenesis inhibitors (see section 4.5), radiotherapy to</p><p>neck and head, corticosteroids.</p></li><li><p>- &nbsp;History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures</p><p>(e.g. tooth extractions) and poorly fitting dentures</p><p>All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic acid Actavis. While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to zoledronic acid administration. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw.</p><p>The management plan for patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of zoledronic acid treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p></li></ul><p><img alt="page5image65932864" width="95.064000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/605449b9-68c8-4479-8afa-13e088ac4943" />&nbsp;<img alt="page5image65941504" width="109.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4f62c727-d9e5-4392-843a-2e55f2bc769a" /></p><p>5</p><p>Osteonecrosis of the external auditory canal<br />Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.</p><p>Musculoskeletal pain<br />In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients that were given zoledronic acid as indicated in sections 4.1 and 4.2. However, such reports have been infrequent. The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged with zoledronic acid or another bisphosphonate.</p><p>Atypical fractures of the femur<br />Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p>Hypocalcaemia<br />Hypocalcaemia has been reported in patients treated with zoledronic acid. Cardiac arrhythmias and neurologic adverse events (including convulsions, hypoaesthesia and tetany) have been reported secondary to cases of severe hypocalcaemia. Cases of severe hypocalcaemia requiring hospitalisation have been reported. In some instances, the hypocalcaemia may be life-threatening (see section 4.8). Caution is advised when zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5). Serum calcium should be measured and hypocalcaemia must be corrected before initiating zoledronic acid therapy. Patients should be adequately supplemented with calcium and vitamin D.</p><p>Acidoxaxcontains sodium<br />This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially&nbsp;&ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, zoledronic acid, used as indicated in sections 4.1 and 4.2, has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring. Zoledronic acid shows no appreciable binding to plasma proteins and does not inhibit human P450 enzymes&nbsp;in vitro&nbsp;(see section 5.2), but no formal clinical interaction studies have been performed.</p><p>Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4).</p><p><img alt="page6image65607296" width="194.780000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/01bbe3af-2f70-49ea-9236-06b22b186fee" />&nbsp;<img alt="page6image65605760" width="94.464000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7910f4bf-0df6-47d2-beb9-593080a774a9" />&nbsp;<img alt="page6image65611520" width="137.060000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/aa4dc884-2e3a-4849-ab81-aaf1ee753ed2" />&nbsp;<img alt="page6image65613056" width="68.520000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ba36ad69-a841-4947-8d28-c40559cc91ce" />&nbsp;<img alt="page6image65604800" width="115.100000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f524fa8a-3f6d-4c23-bcf4-f4e6f100ae51" /></p><p>6</p><p>Caution is indicated when Acidoxaxis used with other potentially nephrotoxic medicinal products. Attention should also be paid to the possibility of hypomagnesaemia developing during treatment.</p><p>In multiple myeloma patients, the risk of renal dysfunction may be increased when Acidoxaxis used in combination with thalidomide.</p><p>Caution is advised when Acidoxaxis administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data on the use of zoledronic acid in pregnant women. Animal reproduction studies with zoledronic acid have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Acidoxaxshould not be used during pregnancy. Women of child-bearing potential should be advised to avoid becoming pregnant.</p><p>Breast-feeding<br />It is not known whether zoledronic acid is excreted into human milk. Acidoxaxis contraindicated in breast-feeding women (see section 4.3).</p><p>Fertility<br />Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. This resulted in exaggerated pharmacological effects considered to be related to the&nbsp;compound&rsquo;s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Acidoxaxalong with driving and operating of machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Within three days after zoledronic acid administration, used as indicated in sections 4.1 and 4.2, an acute phase reaction has commonly been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia, rigors and arthritis with subsequent joint swelling; these symptoms usually resolve within a few days (see description of selected adverse reactions).</p><p>The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease. The frequencies for each of these identified risks are shown in Table 1.</p><p>Tabulated list of adverse reactions<br />The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:</p><p><img alt="page7image65756096" width="46.440000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e7a22de6-6bdf-4e7b-8c8d-14c454712b85" />&nbsp;<img alt="page7image65761472" width="64.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7b5098d0-69d1-4e11-85ce-eb02e6dc19ea" />&nbsp;<img alt="page7image65762048" width="35.760000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c4129593-8585-4560-a36e-7f4859cba9fe" />&nbsp;<img alt="page7image65760896" width="132.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/15216f10-1a3d-4f86-b2d6-f01a29433906" />&nbsp;<img alt="page7image65756864" width="152.180000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b037b09e-f72a-4c35-9425-100b9827fa6b" /></p><p>7</p><p>Table 1</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><img alt="page8image65688256" width="464.020000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/23d308e2-aab4-4ac2-8b06-4d6cb9cdb986" /></p><p>Blood and lymphatic system disorders</p><p>Common: Uncommon: Rare:</p><p>Immune system disorders</p><p>Uncommon:</p><p>Rare:</p><p>Psychiatric disorders</p><p>Uncommon:</p><p>Rare:</p><p>Nervous system disorders</p><p>Anaemia<br />Thrombocytopenia, leukopenia Pancytopenia</p><p>Hypersensitivity reaction Angioneurotic oedema</p><p>Anxiety, sleep disturbance Confusion</p><p>Headache<br />Dizziness, paraesthesia, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence<br />Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia)</p><p>Conjunctivitis<br />Blurred vision, scleritis and orbital inflammation Uveitis<br />Episcleritis</p><p>Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse<br />Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia)</p><p>Dyspnoea, cough, bronchoconstriction Interstitial lung disease</p><p>Nausea, vomiting, decreased appetite Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth</p><p>Pruritus, rash (including erythematous and macular rash), increased sweating</p><p>Bone pain, myalgia, arthralgia, generalised pain Muscle spasms, osteonecrosis of the jaw Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)</p><p>Renal impairment<br />Acute renal failure, haematuria, proteinuria</p><p><img alt="page8image65684992" width="232.010000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/96dc149b-0c7c-4955-adb1-302f2358484a" />&nbsp;<img alt="page8image65695552" width="231.530000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/510f6b63-5109-4937-971d-4dcbe614033a" />&nbsp;<img alt="page8image65694592" width="232.010000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/1b756241-242d-4de8-a996-10b7129df938" /><img alt="page8image65698048" width="231.530000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/b7ed604f-e35e-47c8-a6fc-d08a41a07fd4" />&nbsp;<img alt="page8image65697856" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/707a985c-0e87-4ff4-a748-aede76dce29f" />&nbsp;<img alt="page8image65689216" width="231.530000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a111bea2-7f43-417b-bacf-9545a9e03260" />&nbsp;<img alt="page8image65699200" width="0.480000" height="64.800000" src="blob:https://sdi.sfda.gov.sa/ba804c2f-0cf3-4e18-92d1-4fdb8681743f" />&nbsp;<img alt="page8image65697472" width="0.480040" height="64.800000" src="blob:https://sdi.sfda.gov.sa/b5237685-b05f-4c91-a587-33c474027dda" /><img alt="page8image65686528" width="232.010000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/f1232f4a-f6f2-481c-b6bf-c272e64f5736" />&nbsp;<img alt="page8image65693824" width="231.530000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3d8d27c0-a92f-4aba-b782-bd79468aa7fb" /></p><p>Eye disorders</p><p>Cardiac disorders</p><p>Common: Uncommon:</p><p>Very rare:</p><p>Common: Uncommon: Rare:<br />Very rare:</p><p>Uncommon: Rare:</p><p><img alt="page8image65693248" width="232.010000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4519e59c-3371-45c5-9753-81517dd69fc0" />&nbsp;<img alt="page8image65694400" width="231.530000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b9a2c63d-bfd5-4c82-b4e9-737a4bbca98a" />&nbsp;<img alt="page8image65691520" width="232.010000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/97357d9d-8987-4944-a563-00d5a090a0be" /><img alt="page8image65695360" width="231.530000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/cf93dbc8-fd52-4783-9bfb-f79813b9c6a7" /></p><p>Respiratory, thoracic and mediastinal disorders</p><p>Uncommon:</p><p>Rare:</p><p>Gastrointestinal disorders</p><p>Common: Uncommon:</p><p>Skin and subcutaneous tissue disorders</p><p>Uncommon:</p><p>Musculoskeletal and connective tissue disorders</p><p>Common: Uncommon: Very rare:</p><p>Renal and urinary disorders</p><p>Common: Uncommon:</p><p><img alt="page8image65696320" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d0139dd1-fc54-4014-b104-074d2e7692b0" />&nbsp;<img alt="page8image65694016" width="231.530000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f6ff8884-ec5e-4c88-a757-23002d17392c" />&nbsp;<img alt="page8image65697664" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3cd4a0de-5060-4f32-b871-57e7dbac125b" /><img alt="page8image65699584" width="231.530000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/35a8d78f-d5cf-46ab-8d2b-3c87b4a97d80" />&nbsp;<img alt="page8image65689984" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f58c52c5-532e-4d6b-b36b-92d0fbeb1fa7" />&nbsp;<img alt="page8image65694208" width="231.530000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/42a342c3-3394-4bea-98bb-f0f2767dcf57" /><img alt="page8image65691328" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/de317bee-40d3-4fe3-aaeb-223210288172" />&nbsp;<img alt="page8image65693440" width="231.530000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8e4e9eff-00ce-4846-a688-4476ec6a04fe" />&nbsp;<img alt="page8image65692672" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4cbafb83-2a8b-45db-8544-e922b189d037" /><img alt="page8image65689408" width="231.530000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b2d63ae7-9cc8-4ac4-a994-f77f63f0f16f" />&nbsp;<img alt="page8image65690944" width="232.010000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c2b06cc2-5fa5-43e7-8167-907170388d10" />&nbsp;<img alt="page8image65696512" width="232.250000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8c950dcf-d513-4497-9a85-71c3a5775ace" /></p><p>8</p><p><img alt="page9image65701568" width="464.020000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/61a1c9c5-4bbc-44fb-b3b6-33073dd50bae" /></p><p>General disorders and administration site conditions</p><p><img alt="page9image65708672" width="0.480000" height="77.760000" src="blob:https://sdi.sfda.gov.sa/a2f38ec5-509c-4f6f-b2fd-fbd1ef2a67aa" />&nbsp;<img alt="page9image65702336" width="0.480040" height="77.760000" src="blob:https://sdi.sfda.gov.sa/acdfa6b0-a63e-419c-a00a-9f034b462d93" />&nbsp;<img alt="page9image65714240" width="232.010000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/19252e98-d303-4e12-b82b-65e99cb93e9d" />&nbsp;<img alt="page9image65701760" width="231.530000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4eaf1f36-6b29-4ec3-bcb7-fa19093bcb02" /></p><p>Investigations</p><p>Common: Uncommon:</p><p>Rare:</p><p>Very common: Common:</p><p>Uncommon: Rare:</p><p>Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing)<br />Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria<br />Arthritis and joint swelling as a symptom of acute phase reaction</p><p>Hypophosphataemia<br />Blood creatinine and blood urea increased, hypocalcaemia<br />Hypomagnesaemia, hypokalaemia Hyperkalaemia, hypernatraemia</p><p><img alt="page9image65701376" width="232.010000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/69fe7589-f39e-4d67-a219-82d8f2ebdafe" />&nbsp;<img alt="page9image65708288" width="232.250000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/620485fc-d10f-4bca-acba-6bc85f7bb861" /></p><p>Description of selected adverse reactions</p><p>Renal function impairment</p><p><img alt="page9image65699840" width="181.580000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1550fde7-a8b3-4363-9514-54c04d33caa0" />&nbsp;<img alt="page9image65714432" width="118.700000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1f567a0b-7f29-4d78-973d-d34ab2491e7e" /></p><p>Zoledronic acid, used as indicated in sections 4.1 and 4.2, has been associated with reports of renal dysfunction. In a pooled analysis of safety data from zoledronic acid registration trials for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to zoledronic acid (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4).</p><p>Osteonecrosis of the jaw</p><p>Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4). Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. The majority of the reports refer to cancer patients following tooth extractions or other dental surgeries.</p><p>Atrial fibrillation</p><p>In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3-4 weeks in oncology patients. The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.</p><p>Acute phase reaction</p><p>This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea, arthralgia and arthritis with subsequent joint swelling. The onset time is &le;&nbsp;3 days post-zoledronic acid infusion (used as indicated in sections 4.1 and 4.2), and the reaction is also referred to using the terms &ldquo;flu-like&rdquo; or &ldquo;post-dose&rdquo; symptoms.</p><p>Atypical fractures of the femur</p><p>During post-marketing experience the following reactions have been reported (frequency rare):</p><p><img alt="page9image65855168" width="109.220000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ce6337c5-0e49-4031-8139-41947e5ec490" />&nbsp;<img alt="page9image65856320" width="76.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/38cf248d-c943-4d39-8484-a6ebfd5e9db6" />&nbsp;<img alt="page9image65853248" width="93.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f8d6d76a-ecf4-485c-be32-4becf59828ab" />&nbsp;<img alt="page9image65850176" width="136.100000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7dfc09d5-6a47-4964-ab31-2cc14c8f7df3" /></p><p>9</p><p>Atypical subtrochanteric and diaphyseal femoral fractures (bisphopsphonate class adverse reaction).</p><p>Hypocalcaemia-related ADRs</p><p>Hypocalcaemia is an important identified risk with zoledronic acid in the approved indications. Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between zoledronic acid therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia. Furthermore, there is evidence of an association between hypocalcaemia and secondary neurological events reported in these cases including; convulsions, hypoaesthesia and tetany (see section 4.4).</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E-mail:&nbsp;npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose of zoledronic acid is limited. The administration of doses up to 48 mg of zoledronic acid in error has been reported. Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. In the event of hypocalcaemia, calcium gluconate infusions should be administered as clinically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates, ATC code: M05BA08</p><p>Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption.</p><p>The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. In long-term animal studies, zoledronic acid inhibits bone resorption without adversely affecting the formation, mineralisation or mechanical properties of bone.</p><p>In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several anti-tumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease. The following properties have been demonstrated in preclinical studies:</p><ul><li><p>- &nbsp;In vivo:&nbsp;Inhibition of osteoclastic bone resorption, which alters the bone</p><p>marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic</p><p>activity and anti-pain activity.</p></li><li><p>- &nbsp;In vitro:&nbsp;Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on</p><p>tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.</p><p>Clinical trial results in the prevention of skeletal related events in patients with advanced malignancies involving bone<br />The first randomised, double-blind, placebo-controlled study compared zoledronic acid 4 mg to placebo for the prevention of skeletal related events (SREs) in prostate cancer patients. Zoledronic</p></li></ul><p><img alt="page10image65918208" width="132.980000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a34a43cf-0ed4-4ce2-bcf5-d3c9e8dfc4cb" />&nbsp;<img alt="page10image65926848" width="181.340000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/95b015af-f4dc-4067-be5c-1d5502a7bc16" />&nbsp;<img alt="page10image65916864" width="98.544000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b375a238-71d9-43c3-a3e6-7125e7364e8d" /><img alt="page10image65914944" width="393.670000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/42399c40-d046-41f6-a19e-dd98a4f3516b" />&nbsp;<img alt="page10image65925888" width="127.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/17540889-4913-4f18-8279-00ae295f0700" /></p><p>10</p><p>acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate. Multiple event analysis showed a 36% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. Patients receiving zoledronic acid 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24. Fewer zoledronic acid 4 mg patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions. Efficacy results are provided in Table 2.</p><p>In a second study including solid tumours other than breast or prostate cancer, zoledronic acid 4 mg significantly reduced the proportion of patients with an SRE, delayed the median time to first SRE by &gt; 2 months, and reduced the skeletal morbidity rate. Multiple event analysis showed 30.7% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. Efficacy results are provided in Table 3.</p><p>Table 2:&nbsp;Efficacy results (prostate cancer patients receiving hormonal therapy)</p><p><img alt="page11image65547136" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a3a92eb1-3063-442b-af18-4a251d2f44cc" />&nbsp;<img alt="page11image65546560" width="116.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/03829f68-7c7b-4364-94a3-d4d82af226de" />&nbsp;<img alt="page11image65550784" width="120.260000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f3be1fb0-db5f-4c32-a7fc-94b983995298" />&nbsp;<img alt="page11image65550592" width="121.820000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a3eff1c3-4811-467b-a372-2c1e43c6c1fc" /></p><p>Any SRE (+TIH)</p><p>Fractures*</p><p>Radiation therapy to bone</p><p><img alt="page11image65550976" width="76.440000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d91a83da-5ee0-4b72-8543-3e885ad58d01" />&nbsp;<img alt="page11image65551168" width="46.800000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9cd2da63-0572-4d9c-8f64-8184e494586b" />&nbsp;<img alt="page11image65546752" width="78.984000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/47123314-a7bc-4db3-b670-cd1aa5307635" />&nbsp;<img alt="page11image65551552" width="32.904000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/cee77a35-e32e-43d4-870a-a388846f6989" />&nbsp;<img alt="page11image65551360" width="104.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/fb90bb4b-738f-4359-8017-4db4e5eaac52" />&nbsp;<img alt="page11image65551936" width="63.120000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/053d58bc-744a-44e9-8339-1fe6abc4c19d" />&nbsp;<img alt="page11image65551744" width="52.464000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ccd8293f-00d0-4fc9-9cc5-ebae23e3cf2e" />&nbsp;<img alt="page11image65575488" width="67.080000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7af4de7e-998a-436a-b3bc-5db893433e8c" />&nbsp;<img alt="page11image65569920" width="52.704000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/f4645b26-3f88-41c2-a3ac-90cb1ee502fd" />&nbsp;<img alt="page11image65580096" width="66.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d645c96e-5daa-42c5-b5e7-36b654d52333" />&nbsp;<img alt="page11image65570688" width="54.504000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7212fd54-eb23-4c8c-a80c-20bbbbf4d3d1" /><img alt="page11image65578176" width="104.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/47f97968-3e0a-47dc-8dac-1615ccf0495c" />&nbsp;<img alt="page11image65575872" width="63.120000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4e483517-0057-403f-95d5-de3664030150" />&nbsp;<img alt="page11image65581824" width="52.464000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8b948936-0807-4755-8fab-fdc1d1da27e7" />&nbsp;<img alt="page11image65583168" width="67.080000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e13511d3-4f7a-4a71-b802-0c22c81f64bb" />&nbsp;<img alt="page11image65572032" width="52.704000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c2be1e99-a9db-4570-aecb-a2e70c539a8b" />&nbsp;<img alt="page11image65584704" width="66.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4f9535f3-c20f-4d37-b68a-9faeca4a4416" />&nbsp;<img alt="page11image65579904" width="54.504000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/24db05da-4ee6-4e11-9788-c0233d61f8b4" /></p><p>N<br />Proportion of patients with SREs (%)<br />p-value<br />Median time to SRE (days)<br />p-value<br />Skeletal morbidity rate<br />p-value</p><p>488 0.77</p><p>NR 0.20</p><p>4 mg 208 214</p><p>25 26</p><p>NR NR 0.45 0.42</p><p>0.119 0.055 0.060</p><p>Zoledronic acid<br />4 mg 214<br />38</p><p>0.028 0.009 0.005</p><p>Placebo</p><p>208 49</p><p>321 1.47</p><p>Zoledronic acid<br />4 mg 214<br />17</p><p>0.052 0.020 0.023</p><p>Placebo Zoledronic acid</p><p>Placebo</p><p>208 33</p><p>640 0.89</p><p><img alt="page11image65571456" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6046b185-0e80-41eb-8ec0-551df9b7cf49" />&nbsp;<img alt="page11image65573760" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a06ab6d0-da4e-4b5d-974d-5df4ad12bd3b" />&nbsp;<img alt="page11image65575296" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2f5dd8f9-3ea3-438d-967d-ea075552d482" />&nbsp;<img alt="page11image65582400" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/71cd2ac3-4da5-4c4b-b66a-e0ab2a7f1355" />&nbsp;<img alt="page11image65570112" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1197c580-72b0-4169-8bcd-abada320b543" />&nbsp;<img alt="page11image65576256" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/241812a0-e59e-4586-a9a7-b5df82080184" />&nbsp;<img alt="page11image65581056" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1f2d854e-9a9e-49ab-b00e-46261142e22d" />&nbsp;<img alt="page11image65574144" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1fb0dc7f-bfc7-4ec5-bbbe-31827488972e" />&nbsp;<img alt="page11image65578752" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/40471a85-5a0f-4334-9b03-c7133323bcaf" />&nbsp;<img alt="page11image65579520" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2251cfd5-5e0e-4ab7-a181-fae081c31b88" /><img alt="page11image65582784" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/627e29d5-296f-4942-aaad-7e93dbcc56f1" />&nbsp;<img alt="page11image65584320" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/034158ad-7e38-497d-9ed4-c2c8b88bf668" />&nbsp;<img alt="page11image65572800" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/323f04c4-c8e5-4f71-b76c-d2929302533c" />&nbsp;<img alt="page11image65570304" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/56e0101d-3b46-4b35-b764-1fcec892c416" />&nbsp;<img alt="page11image65577600" width="104.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/44909a43-f7fd-4071-b175-765cfbe3ddeb" />&nbsp;<img alt="page11image65572992" width="63.120000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e8fd056b-4ef1-40b0-b811-968aff29d70b" />&nbsp;<img alt="page11image65578368" width="52.464000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/44d16eb2-4c6b-40ea-a806-2cdb2a590984" />&nbsp;<img alt="page11image65643328" width="67.080000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/97974bdf-24ae-4336-a413-84a8390d664c" />&nbsp;<img alt="page11image65634496" width="52.704000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8446f214-5a48-489b-a47d-00b4b8e1cf1a" />&nbsp;<img alt="page11image65638912" width="66.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ba34eb26-3c34-49e6-baac-7c1e5e1be671" />&nbsp;<img alt="page11image65634688" width="54.504000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/f106b3d2-ac49-448b-8e71-922cc968f5fc" /><img alt="page11image65646208" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2edde1ff-0c9b-4234-9adb-9ca0a2f3fab5" />&nbsp;<img alt="page11image65644096" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d089bd0a-92a2-4e2a-812e-e083042f0ae6" />&nbsp;<img alt="page11image65637760" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e1aa6f83-8871-4b6a-b710-5d0c2e335530" />&nbsp;<img alt="page11image65641024" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1bbeee54-696b-4b33-a383-aead2d5b6bd5" />&nbsp;<img alt="page11image65640832" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ff0697f7-b23a-4234-85d1-7a23de091caf" />&nbsp;<img alt="page11image65644480" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ad649360-cbf2-48cf-b3e9-34d0c21513f6" />&nbsp;<img alt="page11image65647360" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/436664b3-d8d2-4d26-864e-04c65a8780fa" />&nbsp;<img alt="page11image65641984" width="104.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/811b373b-6b6c-4e01-a2f8-2bb0cc453be4" />&nbsp;<img alt="page11image65649088" width="63.120000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/6397f83c-e5b8-44b2-af7d-1010331c44ad" />&nbsp;<img alt="page11image65636608" width="52.464000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/79a3275e-b27c-4caa-ac8b-a5319331ad98" /><img alt="page11image65638144" width="67.080000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/bb4a295c-812c-4160-8c58-940bc405adb6" />&nbsp;<img alt="page11image65639104" width="52.704000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2bb6cd7a-95ac-45ac-9bf4-57fab83d4ddc" />&nbsp;<img alt="page11image65642368" width="66.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e87041c8-0269-4adf-8def-75a8d1868e91" />&nbsp;<img alt="page11image65639296" width="54.504000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/5cde5562-4f90-448d-999e-89b9f3f4d0cd" />&nbsp;<img alt="page11image65638336" width="104.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b5ef43b3-7ac5-45eb-a19d-32ca2d46ccce" />&nbsp;<img alt="page11image65637184" width="63.120000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/23f47359-c70b-49f0-b26d-3c4bbc0b1569" />&nbsp;<img alt="page11image65639488" width="52.464000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d19e3c1d-82b2-4ae5-9f2a-25bf67147a1a" />&nbsp;<img alt="page11image65640064" width="67.080000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/94b69eca-c23e-417a-8f97-15848e834669" />&nbsp;<img alt="page11image65643136" width="52.704000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/efa23c70-38f1-4f3e-b7f0-5b6b18732833" />&nbsp;<img alt="page11image65643904" width="66.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/99ba10ba-6377-4975-914e-fcf3d37bdc8e" />&nbsp;<img alt="page11image65639680" width="54.504000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d44b3e2f-421d-4166-aba1-eca702a9d88f" /></p><table><tbody><tr><td><p>Risk reduction of suffering from multiple events** (%)</p></td><td><p>36</p></td><td><p>-</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>NA</p></td></tr></tbody></table><p>p-value<br />* Includes vertebral and non-vertebral fractures<br />** Accounts for all skeletal events, the total number as well as time to each event during the trial NR Not Reached<br />NA Not Applicable</p><p>0.002</p><p>Table 3:&nbsp;Efficacy results (solid tumours other than breast or prostate cancer)</p><p>NA</p><p>NA</p><p>Radiation therapy to bone</p><p><img alt="page11image65692480" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3659dcb9-8dce-49fa-b5c2-67656c34353e" />&nbsp;<img alt="page11image65691136" width="116.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fb28a382-4c18-4288-9578-dec53c31a219" />&nbsp;<img alt="page11image65696128" width="120.260000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5eee537e-84aa-4f57-811c-3d3df44c8cf3" />&nbsp;<img alt="page11image65690560" width="121.820000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/025026e5-859f-475e-85ff-b283aca2f716" />&nbsp;<img alt="page11image65695936" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0824ddee-32da-4f26-adf0-cc8573d584fa" />&nbsp;<img alt="page11image65685376" width="116.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4a24c42d-a737-4978-9635-189ff42377a1" /><img alt="page11image65727744" width="120.260000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b7c582be-820c-4611-86d6-bdf3cdb60830" />&nbsp;<img alt="page11image65725632" width="121.820000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4da910b4-777e-4696-b55c-ca3e18f57ae1" /></p><p>Any SRE (+TIH)</p><p>Fractures*</p><p><img alt="page11image65723904" width="76.440000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7db875ed-f5fa-4a81-99c9-08bb3eb8fd3b" />&nbsp;<img alt="page11image65728704" width="46.800000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/77501dfd-1b37-40ba-b6f5-fb300e53b2f0" />&nbsp;<img alt="page11image65728128" width="78.984000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3128b068-9f39-4bc1-b987-edf640a7e452" />&nbsp;<img alt="page11image65732160" width="32.904000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/6a2d6616-b344-4436-b01c-11c139bf1757" />&nbsp;<img alt="page11image65720064" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/aca8b539-b44b-4807-bab2-017596af7b9b" />&nbsp;<img alt="page11image65731776" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c7b40615-1635-463c-8de6-75e3252357fc" />&nbsp;<img alt="page11image65732352" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b933a195-d349-4d9e-9472-f8f076e33a86" />&nbsp;<img alt="page11image65727552" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2b281635-a958-4ce4-96a8-14ca09e216ee" />&nbsp;<img alt="page11image65730624" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b652aea2-2823-42db-a0dd-b0108fe9542e" />&nbsp;<img alt="page11image65717760" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/02282def-a1d8-4555-b894-1e66b4a21553" />&nbsp;<img alt="page11image65729280" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f83a9548-5592-4e85-8989-6062bb153693" /></p><p>Zoledronic acid<br />4 mg</p><p>N 257 Proportion of 39 patients with SREs<br />(%)</p><p>p-value</p><p>Placebo</p><p>250 48</p><p>Zoledronic acid<br />4 mg 257<br />16</p><p>Placebo Zoledronic acid</p><p>4 mg 250 257</p><p>22 29</p><p>Placebo</p><p>250 34</p><p><img alt="page11image65722752" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/16a2dddc-8f44-4e65-b1de-81d5b789eb50" />&nbsp;<img alt="page11image65720640" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1e928ad8-fcf2-4f18-bad7-bea951627c3f" />&nbsp;<img alt="page11image65730816" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3113b2c6-a2f2-4489-921f-8734f052b738" />&nbsp;<img alt="page11image65729664" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8a44ebc4-a3a7-42ee-9b8e-b73a81c41c59" />&nbsp;<img alt="page11image65726400" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7e005e20-3eaa-4748-8b7d-61614e0beeba" />&nbsp;<img alt="page11image65721600" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/70054f27-f076-448c-8255-c7a59d95c3ef" />&nbsp;<img alt="page11image65717568" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/861655d1-0bb6-41fc-ae27-f786640105a7" />&nbsp;<img alt="page11image65731008" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1d6b4dd3-48b7-4747-8396-9b272c20f9dd" />&nbsp;<img alt="page11image65719104" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6df3fd02-851a-4fee-83ff-092d6f4fd295" />&nbsp;<img alt="page11image65727360" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3296fe76-d609-41b2-a29f-97b8015027a7" /><img alt="page11image65730048" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5911fea6-f486-4073-bb33-10c89a59d7fa" />&nbsp;<img alt="page11image65729472" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/134f99e5-51bb-429a-a39f-87382a552d79" />&nbsp;<img alt="page11image65719296" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/563229a9-4c0c-4f88-a828-ec000a5758d4" />&nbsp;<img alt="page11image65712896" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/123d76d6-5a5e-4a79-9299-8d87a593a023" />&nbsp;<img alt="page11image65709056" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/578473f8-049d-460d-89c3-382458ae6334" />&nbsp;<img alt="page11image65703104" width="63.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/89f0fb9d-d92a-445c-9816-37e2163a9aef" />&nbsp;<img alt="page11image65712512" width="52.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/21fc2d5d-8d4a-412f-b9d0-2deb0e4e19fd" />&nbsp;<img alt="page11image65713664" width="67.080000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/be3de3ff-f714-4b25-bfad-5cd2e698e830" />&nbsp;<img alt="page11image65712320" width="52.704000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8bdabdfb-fac2-4482-800d-fc6318aa734d" />&nbsp;<img alt="page11image65701952" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/99e112c2-ec7d-489a-ad6c-7e6f859a76c8" />&nbsp;<img alt="page11image65704064" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3e191c6d-bf0d-4f0f-85dc-7a54a0d40c52" /></p><p>0.039</p><p>0.064</p><p>0.173</p><p><img alt="page11image65707904" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4bcea2d8-57cd-409b-aa78-3dcb4e417c0f" />&nbsp;<img alt="page11image65713856" width="116.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5a1cfb8e-7cc3-48e2-8ca5-cb25554c6d68" />&nbsp;<img alt="page11image65703296" width="120.260000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fa64d20a-2112-4159-a4e3-c6f18534ad03" />&nbsp;<img alt="page11image65715200" width="121.820000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e6df7dd2-dc01-4ced-ab16-15955d99639e" /></p><p>11</p><p><img alt="page12image66030208" width="104.420000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/8da53711-9353-40ea-b2e5-afb6a1ce8b8e" />&nbsp;<img alt="page12image66030400" width="116.060000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/e68d9a60-46c5-401b-aa3d-a06a87292316" />&nbsp;<img alt="page12image66030592" width="120.260000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/66a6ef5f-a0a5-4b0b-b671-509fae2a2639" />&nbsp;<img alt="page12image66030784" width="121.820000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/48b461ad-d44e-4108-9b41-c562324b143a" /></p><p>Any SRE (+TIH)</p><p>Fractures*</p><p>Radiation therapy to bone</p><p><img alt="page12image66030976" width="76.440000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/29e9a288-a1fd-4f14-8352-489ffe1143f2" />&nbsp;<img alt="page12image66031168" width="46.800000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/fab016fd-e261-40a3-8dbc-a73941c7b6c6" />&nbsp;<img alt="page12image66031360" width="78.984000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/6c3fe9b7-593c-4e96-9a42-c8f6ede1e683" />&nbsp;<img alt="page12image66031552" width="32.904000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/150e0665-3b5a-490b-b2ac-613c14e658e5" />&nbsp;<img alt="page12image66031744" width="104.420000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/9262443b-c825-4e22-91aa-d2875d7820f4" />&nbsp;<img alt="page12image66031936" width="63.120000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/dd8c634c-055d-4e2a-b25b-08ad3d33c6f7" />&nbsp;<img alt="page12image66032128" width="52.464000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/b72f4b5d-4000-498d-a22e-2057f33243ce" />&nbsp;<img alt="page12image66032320" width="67.080000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/1a2a30ba-8b00-4373-9ee2-20cdda0b9213" />&nbsp;<img alt="page12image66032512" width="52.704000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/052ba3d6-3f71-4e78-8563-36aad2b3df59" />&nbsp;<img alt="page12image66032704" width="66.840000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/43660747-ba44-4532-b480-f18755e463f4" />&nbsp;<img alt="page12image66032896" width="54.504000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c3ebd8b1-d013-4152-9cf9-a13a61ccfd00" /><img alt="page12image66033088" width="63.120000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/4a46e872-5fb1-45f2-a0fc-043efbfc0611" />&nbsp;<img alt="page12image66033280" width="52.464000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a2715ed1-9400-4c7a-9ecc-6dcc52c83575" />&nbsp;<img alt="page12image66033472" width="67.080000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/30fb88e2-2e3a-4523-bea2-edd859663c7c" />&nbsp;<img alt="page12image66033664" width="52.704000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/24b351a4-3bee-454f-aa8e-b73f982e5f91" />&nbsp;<img alt="page12image66033856" width="66.840000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/f1642126-b9a2-424c-ba25-44b1c506ced4" />&nbsp;<img alt="page12image66034048" width="54.504000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7f01e262-3df8-4521-aad8-2949659eeec6" /></p><p>Median time to SRE (days)<br />p-value<br />Skeletal morbidity rate</p><p>p-value</p><p>1.74</p><p>0.39</p><p>4 mg NR 424</p><p>0.63 1.24</p><p>0.079 0.099</p><p>Zoledronic acid<br />4 mg 236</p><p>0.009 0.012</p><p>Placebo 155 2.71</p><p>Zoledronic acid<br />4 mg NR</p><p>0.020 0.066</p><p>Placebo Zoledronic acid</p><p>Placebo 307 1.89</p><p><img alt="page12image66034240" width="104.420000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/ce32a9b4-2cd5-4c80-b583-2cf707c00fcb" />&nbsp;<img alt="page12image66034432" width="104.420000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/0441d84e-fcf9-431b-830c-71b989c2126c" />&nbsp;<img alt="page12image66034624" width="63.120000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c7dc0d0f-3574-4156-8f05-2d5cdc3fc92e" />&nbsp;<img alt="page12image66034816" width="52.464000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/9e38f557-123c-4fea-9455-98db73fa97df" />&nbsp;<img alt="page12image66035008" width="67.080000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/b75613f6-8014-490e-b2c7-13baddde1203" />&nbsp;<img alt="page12image66035200" width="52.704000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/96a71dfb-1f0a-4ab3-b83a-56bc8774fcf1" />&nbsp;<img alt="page12image66035392" width="66.840000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/3f1fa3f1-ede7-40b2-92ae-eea9955cd1e2" />&nbsp;<img alt="page12image66035584" width="54.504000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/dfa1ebe9-4ce8-4d30-b334-60f32bfa1613" />&nbsp;<img alt="page12image66035776" width="104.420000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/4e5e13d4-7951-4435-b089-22f39408cc06" />&nbsp;<img alt="page12image66035968" width="63.120000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/2d6439f0-b033-4882-95fd-8bb7cf3a9647" /><img alt="page12image66036160" width="52.464000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7f09b2b7-8741-44a0-b4da-25c0a546d066" />&nbsp;<img alt="page12image66036352" width="67.080000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/0c39d4b7-a65f-4d01-90c9-3e853b0386df" />&nbsp;<img alt="page12image66036544" width="52.704000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/3577d1e2-65bc-443f-be07-8523c7d3dd4a" />&nbsp;<img alt="page12image66036736" width="66.840000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/6f196a6b-ef99-4c5d-882f-a11d2ebcd764" />&nbsp;<img alt="page12image66036928" width="54.504000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/d7802f69-e8a7-4781-b5a0-fdf46190e22c" />&nbsp;<img alt="page12image66037120" width="104.420000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a3a0b356-2fef-4ff0-95c3-e951b869b9e9" />&nbsp;<img alt="page12image66037312" width="63.120000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a8c0739b-d21f-45d2-bfd5-6815896faf54" />&nbsp;<img alt="page12image66037504" width="52.464000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/f2c3d869-5661-403c-8c8c-4bd1128dd539" />&nbsp;<img alt="page12image66037696" width="67.080000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/0f33871e-57ec-416c-90f8-328c416bf25d" />&nbsp;<img alt="page12image66037888" width="52.704000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/792e2e47-7c74-419f-bc44-c5bcf6075809" />&nbsp;<img alt="page12image66038080" width="66.840000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/1f41f39b-b643-4e8f-8d9c-924361477ce1" /><img alt="page12image66038272" width="54.504000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7e973a6c-a85b-4fba-8034-9ab982d1b9ef" /></p><table><tbody><tr><td><p>Risk reduction of suffering from multiple events** (%)</p></td><td><p>30.7</p></td><td><p>-</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>NA</p></td></tr></tbody></table><p>p-value<br />* Includes vertebral and non-vertebral fractures<br />** Accounts for all skeletal events, the total number as well as time to each event during the trial NR Not Reached<br />NA Not Applicable</p><p>In a third phase III randomised, double-blind trial, 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. The results demonstrated that 4 mg zoledronic acid showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. The multiple event analysis revealed a significant risk reduction of 16% in patients treated with 4 mg zoledronic acid in comparison with patients receiving pamidronate. Efficacy results are provided in Table 4.</p><p>0.003</p><p>NA</p><p>NA</p><p><img alt="page12image66042688" width="104.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1b589967-5389-4404-856f-220114ad75bc" />&nbsp;<img alt="page12image66042880" width="116.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d47286a6-d6d1-4c51-846e-1f22d03d185a" />&nbsp;<img alt="page12image66043072" width="120.260000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fc2be7f3-2260-4641-be36-cb5c3cf00527" />&nbsp;<img alt="page12image66043264" width="121.820000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/837dd9d2-d072-407e-9665-54fbdc5012ee" /></p><p>Table 4:&nbsp;Efficacy results (breast cancer and multiple myeloma patients)</p><p><img alt="page12image66043456" width="105.140000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9275a50b-940e-4a74-8add-086618a38789" />&nbsp;<img alt="page12image66043648" width="115.700000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/da0e2e47-c9f3-421a-9b23-8cb207f377ca" />&nbsp;<img alt="page12image65904320" width="120.140000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b3ee2de4-892b-4f49-baf9-913310ebf8dd" />&nbsp;<img alt="page12image65911232" width="121.580000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/269de48b-3813-4c19-8bb3-72b0fc65f624" /></p><p>Any SRE (+TIH)</p><p>Fractures* Zoledronic</p><p>Radiation therapy to bone</p><p><img alt="page12image65901056" width="76.440000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e024eedd-80dd-444d-b045-f195ca177650" />&nbsp;<img alt="page12image65909120" width="46.800000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/02b15f34-338d-44db-90bd-bf55f4d8bd75" />&nbsp;<img alt="page12image65908544" width="78.984000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1f6ad92f-d824-4739-90bb-c3b44142da90" />&nbsp;<img alt="page12image65902208" width="32.904000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/010146aa-26b8-4f5c-9a2e-1591de080092" />&nbsp;<img alt="page12image65903936" width="105.140000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3e948734-d7e2-4727-92db-214934bfa64c" />&nbsp;<img alt="page12image65910272" width="66.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9da5bce4-59b2-4adb-91d2-e1fed87353a6" />&nbsp;<img alt="page12image65908736" width="48.384000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8b333d1a-a151-4fe3-a00a-e85243359a61" />&nbsp;<img alt="page12image65907392" width="66.120000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/46767066-09ee-4077-bde8-d4b893f7b305" />&nbsp;<img alt="page12image65905856" width="53.544000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/804ce22b-4c9b-44a9-af33-f6cdc6684b55" />&nbsp;<img alt="page12image65910848" width="66.600000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/93fd4f4e-cbf7-4583-802d-18495c36462d" />&nbsp;<img alt="page12image65897600" width="54.504000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1c4a71ca-3635-4b39-b266-0335fedaf0bd" /></p><p>Pam Zoledronic 90 mg acid<br />4 mg 561 555 561 555 561</p><p>Pam 90 mg</p><p>555 24</p><p>Zoledronic acid<br />4 mg</p><p>Pam 90 mg</p><p>acid 4 mg</p><p><img alt="page12image65552960" width="105.140000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/9acc66e0-27db-4515-9e32-84335ba8b0cb" />&nbsp;<img alt="page12image65552768" width="66.840000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/f9d4c63b-ebfd-43d6-911f-ee082de6177e" />&nbsp;<img alt="page12image65556608" width="48.384000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/edb682ef-4743-49a9-a2f3-6b4298f84a7e" />&nbsp;<img alt="page12image65560832" width="66.120000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/0b578eac-d491-4c7a-ab31-3690a029e138" />&nbsp;<img alt="page12image65553344" width="53.544000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/4c94733c-19da-4d1a-8a38-c1f40da5d8cb" />&nbsp;<img alt="page12image65555840" width="66.600000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/a803d7ae-e464-43a0-aaf8-da6167c11f83" />&nbsp;<img alt="page12image65555264" width="54.504000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/4aefc1b4-2b76-4a40-ad42-8344b9a20bde" /></p><p>N<br />Proportion of patients with SREs (%)<br />p-value<br />Median time to SRE (days)<br />p-value<br />Skeletal morbidity rate<br />p-value</p><p>48</p><p>376 1.04</p><p>52</p><p>356<br />1.39 0.53</p><p><img alt="page12image65553152" width="105.140000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/4e1a5988-0bf0-47bc-9ac8-bd0edbc11684" />&nbsp;<img alt="page12image65560064" width="66.840000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/befc4b80-a424-4ba6-8965-78eb3a65ebe6" />&nbsp;<img alt="page12image65558528" width="48.384000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/956dbbe0-4f60-403e-b6d1-1a6eb1c939ed" />&nbsp;<img alt="page12image65558912" width="66.120000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/d8dc3b5a-1315-4fb4-8210-0b48dc3983e9" />&nbsp;<img alt="page12image65561984" width="53.544000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/c28a87e1-f17f-454e-94d9-40391c46cf8a" />&nbsp;<img alt="page12image65560640" width="66.600000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/a337bcce-d01b-4f2f-a546-3430176f1322" />&nbsp;<img alt="page12image65554688" width="54.504000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/72b7b7fa-a454-4bfa-8a34-57ed48051480" /></p><p>37</p><p>39 19</p><p>0.653<br />714 NR</p><p><img alt="page12image65555456" width="105.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/89b6e37b-7176-4b3d-bfd5-ae652b4015a8" />&nbsp;<img alt="page12image65555072" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/47eabb16-3491-4eb2-bc87-95203feb71db" />&nbsp;<img alt="page12image65925504" width="48.384000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/21b873c2-2e91-4ca7-9766-29a9e2ea7828" />&nbsp;<img alt="page12image65927616" width="66.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/083b81ca-6cf6-458a-94a2-e35765ecd387" />&nbsp;<img alt="page12image65918016" width="53.544000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c95b0c76-dff3-422d-bddf-6f0ed28e8f1d" />&nbsp;<img alt="page12image65917056" width="66.600000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6a4c239b-67cc-4167-a657-483647b32418" />&nbsp;<img alt="page12image65920704" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/af93319c-68fa-43ea-96e2-5c1d8cc71313" /></p><p>0.198 0.151 0.084</p><p>NR</p><p>0.037<br />NR</p><p>0.026 0.015</p><p><img alt="page12image65926464" width="105.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b01ba37a-c784-4910-822d-b29ebf2b1b50" />&nbsp;<img alt="page12image65924928" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/46d42811-6690-4f13-a0ee-573743d8ce12" />&nbsp;<img alt="page12image65921280" width="48.384000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/610b478b-e841-4f3d-9bcd-9317ce4418c4" />&nbsp;<img alt="page12image65918784" width="66.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e5d30ccb-fe4e-4ada-afb6-9dae20502dea" />&nbsp;<img alt="page12image65916096" width="53.544000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1bef6f92-e1f3-4de1-96c0-5243694629d9" />&nbsp;<img alt="page12image65919936" width="66.600000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/00948519-7997-42ac-8a16-f5284d815033" />&nbsp;<img alt="page12image65915904" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6cdf47fd-5585-428a-ba83-92663731e77b" />&nbsp;<img alt="page12image65924352" width="105.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d3105b45-a705-4f32-b01b-d6025300e1df" />&nbsp;<img alt="page12image65913600" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6b1c6e05-fec0-4d8f-a487-8ec0b1925f2c" />&nbsp;<img alt="page12image65920512" width="48.384000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/92327dc7-2f30-466a-957a-d2dd5e460803" /><img alt="page12image65918592" width="66.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d6ee7b7b-4fbf-4398-ab6c-b266b747a10f" />&nbsp;<img alt="page12image65920896" width="53.544000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6bd657b7-5a47-4d23-ba1f-8b12b435c61c" />&nbsp;<img alt="page12image65915136" width="66.600000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a6854f87-621d-448c-b626-b95879515719" />&nbsp;<img alt="page12image65919168" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e8fd2faf-d9ca-4af3-86fa-c49fba806997" /></p><p>0.672 0.614</p><p>0.60 0.47</p><p>0.71</p><p><img alt="page12image65924544" width="105.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a948b7ec-074c-4be5-a2d5-492f595a2d5e" />&nbsp;<img alt="page12image65923776" width="66.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ade15157-fad5-4c00-89db-528c098d0d9f" />&nbsp;<img alt="page12image65917632" width="48.384000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f1963ab3-7e62-465c-80fa-616f91bdc6af" />&nbsp;<img alt="page12image65913024" width="66.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e078b046-3431-4370-9a15-810b0ab60618" />&nbsp;<img alt="page12image65921088" width="53.544000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2f3dc58f-b644-4d39-98ca-b7bb44df8087" />&nbsp;<img alt="page12image65924736" width="66.600000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e84f8e1f-4267-44a8-a94b-f078348e2835" />&nbsp;<img alt="page12image65927808" width="54.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5fdad773-a5f2-4b7f-8ed6-80b66518f2da" />&nbsp;<img alt="page12image65919360" width="105.140000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/d7d53cdf-bfbe-48e1-92e3-9a921d05b05f" />&nbsp;<img alt="page12image65917824" width="66.840000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/0b8fe741-707e-4fde-bde9-68a8214cb9f4" />&nbsp;<img alt="page12image65914752" width="48.384000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/38dd6f4e-7b3e-46b8-8e7c-9911324c33b1" /><img alt="page12image65917248" width="66.120000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/5a563679-47bf-4034-83b1-c246336c763d" />&nbsp;<img alt="page12image65928192" width="53.544000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/2f2b3d23-a3f4-4707-84bf-9bee986a260a" />&nbsp;<img alt="page12image65916480" width="66.600000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/6c2523ff-2e6e-4d53-b46f-90206551b945" />&nbsp;<img alt="page12image65918400" width="54.504000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/b22f2566-953a-4d39-8c5e-2e58c8d0ccf4" /></p><table><tbody><tr><td><p>Risk reduction of suffering from multiple events** (%)</p></td><td><p>16</p></td><td><p>-</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>NA</p></td></tr></tbody></table><p>p-value<br />* Includes vertebral and non-vertebral fractures<br />** Accounts for all skeletal events, the total number as well as time to each event during the trial NR Not Reached<br />NA Not Applicable</p><p>0.030</p><p>NA</p><p>NA</p><p><img alt="page12image65926272" width="105.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2de6c82f-9c86-4042-b806-997acab20522" />&nbsp;<img alt="page12image65926080" width="115.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/69c1e3dc-b7c1-456b-848c-b95c6f2e2ea2" />&nbsp;<img alt="page12image65921472" width="120.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/25e48b4f-5e40-4a67-bfa1-5d64ab62f1f1" />&nbsp;<img alt="page12image65928768" width="121.580000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5a2dfa32-d9c7-44e6-9bc5-67cdb292c4ad" /></p><p>12</p><p>Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in<br />228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period. Patients received either 4 mg zoledronic acid or placebo every four weeks for one year. Patients were evenly distributed between zoledronic acid-treated and placebo groups.</p><p>The SRE rate (events/person year) was 0.628 for zoledronic acid and 1.096 for placebo. The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid-treated group versus 49.6% in the placebo group (p=0.003). Median time to onset of the first SRE was not reached in the zoledronic acid-treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.</p><p>In the zoledronic acid-treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1). The pain score for zoledronic acid was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score.</p><p>Figure 1: Mean changes from baseline in BPI scores. Statistically significant differences are marked (*p&lt;0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo)</p><p>Placebo Zoledronic acid</p><p>Time on study (weeks)</p><p>Clinical trial results in the treatment of TIH<br />Clinical studies in tumour-induced hypercalcaemia (TIH) demonstrated that the effect of zoledronic acid is characterised by decreases in serum calcium and urinary calcium excretion. In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2-2.5 mg.</p><p>To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid. The following response rates were observed:</p><p><img alt="page13image50966720" width="334.200000" height="223.450000" src="blob:https://sdi.sfda.gov.sa/1401097c-ba88-4b4c-8bfc-952eb7a8713b" />&nbsp;<img alt="page13image65906816" width="17.000000" height="185.900000" src="blob:https://sdi.sfda.gov.sa/ffce1a23-8b75-4fe7-888a-99382b6dc3ed" />&nbsp;<img alt="page13image65902976" width="192.980000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/16d5cae4-8c91-42ae-81b9-bbac6721c8bf" /></p><p>13</p><p>BPI mean change from baseline</p><p>Table 5:&nbsp;Proportion of complete responders by day in the combined TIH studies</p><p><img alt="page14image65923584" width="146.660000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/185e2959-2fbc-4ee5-8618-f6cf64582f2b" />&nbsp;<img alt="page14image65922624" width="105.980000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/de687fbf-fdc1-47b0-b708-3d23f5297e7f" />&nbsp;<img alt="page14image65927232" width="112.940000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/37603f51-4421-45de-9e37-2eebd464aadd" />&nbsp;<img alt="page14image65923200" width="101.780000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/0f481d47-1937-4edb-8193-96f81c67c35d" /></p><p>Day 4 Zoledronic acid 4 mg (N=86) 45.3% (p=0.104)</p><p>Zoledronic acid 8 mg (N=90) 55.6% (p=0.021)* Pamidronate 90 mg (N=99) 33.3%<br />*p-values compared to pamidronate.</p><p>Day 7<br />82.6% (p=0.005)* 83.3% (p=0.010)* 63.6%</p><p>Day 10<br />88.4% (p=0.002)* 86.7% (p=0.015)* 69.7%</p><p><img alt="page14image66013440" width="146.660000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7f7a0b2d-0b39-4191-8c5c-600bb42502be" />&nbsp;<img alt="page14image65998208" width="105.980000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/b8ead82d-bf5f-4527-adce-eef3f3cb547f" />&nbsp;<img alt="page14image65998016" width="112.940000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/ddf60c85-75f1-420b-b86b-4265253d490b" />&nbsp;<img alt="page14image66046784" width="101.780000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/2cc4a214-e9be-46d4-8ef5-ccd5c93c86ca" />&nbsp;<img alt="page14image66057344" width="146.660000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/b95b6160-c6cc-4ef4-aacd-181288e9f250" />&nbsp;<img alt="page14image65598208" width="105.980000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/92c7432b-eacc-4c46-994a-117a183275fa" /><img alt="page14image65601280" width="112.940000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/4acd6f06-6580-4616-bce0-eb07e94dbe5f" />&nbsp;<img alt="page14image65760704" width="101.780000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/fec00b42-d379-4795-8056-776debfddc1d" />&nbsp;<img alt="page14image65773056" width="146.660000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/cb4405a2-ae16-429d-b135-1485eb9fa5b2" />&nbsp;<img alt="page14image65775936" width="105.980000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/5623d26d-6411-42d2-9fa5-f696d63bedd8" />&nbsp;<img alt="page14image65257472" width="112.940000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/4b227a7f-adbb-42b5-9097-0fe247671d2d" />&nbsp;<img alt="page14image65261888" width="101.780000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/b7758f21-0972-4233-af67-f9691ff6fbfe" /><img alt="page14image65259008" width="146.660000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7ee57029-5109-4bd0-83df-9c506b70a1a0" />&nbsp;<img alt="page14image65269952" width="105.980000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/f3cc4616-46ce-4e5a-9ab2-51b282511dfc" />&nbsp;<img alt="page14image65265344" width="112.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/aa8baf35-a8a8-4b90-8d49-7a211c067f73" />&nbsp;<img alt="page14image65264192" width="101.780000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2fc57191-ab66-4bac-a9b9-a482d6ae1a5c" /><img alt="page14image65264384" width="468.820000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/546b6139-12de-4b3b-82d6-fd5cab4c9490" /></p><p>Median time to normocalcaemia was 4 days. Median time to relapse (re-increase of albumin-corrected serum calcium&nbsp;&ge;&nbsp;2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus<br />17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid). There were no statistically significant differences between the two zoledronic acid doses.</p><p>In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid. The response rate in these patients was about 52%. Since those patients were retreated with the 8 mg dose only, there are no data available allowing comparison with the 4 mg zoledronic acid dose.</p><p>In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.</p><p>Paediatric population</p><p>Clinical trial results in the treatment of severe osteogenesis imperfecta in paediatric patients aged<br />1 to 17 years<br />The effects of intravenous zoledronic acid in the treatment of paediatric patients (age 1 to 17 years) with severe osteogenesis imperfecta (types I, III and IV) were compared to intravenous pamidronate in one international, multicentre, randomised, open-label study with 74 and 76 patients in each treatment group, respectively. The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks. In the clinical programme patients aged 1 to &lt; 3 years received 0.025 mg/kg zoledronic acid (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg zoledronic acid (up to a maximum single dose of 0.83 mg) every 3 months. An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study.</p><p>The primary endpoint of the study was the percent change from baseline in lumbar spine bone mineral density (BMD) after 12 months of treatment. Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid. In particular there was no clear evidence of efficacy on incidence of fracture or on pain. Fracture adverse events of long bones in the lower extremities were reported in approximately 24% (femur) and 14% (tibia) of zoledronic acid-treated patients vs 12% and 5% of pamidronate-treated patients with severe osteogenesis imperfecta, regardless of disease type and causality but overall incidence of fractures was comparable for the zoledronic acid and pamidronate-treated patients: 43% (32/74) vs 41% (31/76). Interpretation of the risk of fracture is confounded by the fact that fractures are common events in patients with severe osteogenesis imperfecta as part of the disease process.</p><p>The type of adverse reactions observed in this population were similar to those previously seen in adults with advanced malignancies involving the bone (see section 4.8). The adverse reactions ranked under headings of frequency, are presented in Table 6. The following conventional classification is used: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><img alt="page14image65257664" width="94.584000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f4ed158e-329f-434b-9b54-aa08ca70860b" />&nbsp;<img alt="page14image65257856" width="436.540000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0307c80a-9190-4592-bfcd-5556967841a5" />&nbsp;<img alt="page14image65260544" width="57.480000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b7f57b44-6013-45bf-87aa-380d957b5f4c" /></p><p>14</p><p>Table 6:&nbsp;Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta1&nbsp;Nervous system disorders</p><p><img alt="page15image65267648" width="230.450000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/30badca8-a102-480b-90c2-243fe0c43764" />&nbsp;<img alt="page15image65273600" width="230.090000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/2c85001b-f9f5-47c6-9625-8df937b611ac" />&nbsp;<img alt="page15image65259392" width="230.450000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/6d9c5180-07e3-47bf-81c3-48c384c5226e" /><img alt="page15image65269760" width="230.090000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/ef8710f4-d484-4b18-a272-3a6bede587f7" /></p><p>Cardiac disorders</p><p>Common:</p><p>Common:</p><p>Headache Tachycardia</p><p>Nasopharyngitis</p><p>Vomiting, nausea Abdominal pain</p><p>Pain in extremities, arthralgia, musculoskeletal</p><p>pain</p><p><img alt="page15image65269568" width="230.450000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/fe198dc5-7539-46bd-98cf-2809206b57a4" />&nbsp;<img alt="page15image65268224" width="230.090000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/47d915d7-34b6-42f8-bf10-40f41f05da8d" /></p><p>Respiratory, thoracic and mediastinal disorders</p><p>Common:</p><p>Gastrointestinal disorders</p><p>Very common:</p><p>Common:</p><p>Musculoskeletal and connective tissue disorders</p><p>Common:</p><p>General disorders and administration site conditions</p><p><img alt="page15image65273216" width="230.450000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/092dbcab-cc0a-48d8-910a-c899ebd7186f" />&nbsp;<img alt="page15image65265152" width="230.090000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/12f1b423-2099-4c28-97d1-a22b4559ba1f" />&nbsp;<img alt="page15image65259584" width="230.450000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4aebe511-c9e1-45b0-8191-1cccb5e168d7" /><img alt="page15image65258432" width="230.090000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7e606c3f-81ce-4d90-8109-3a03e9fdea29" />&nbsp;<img alt="page15image65262080" width="230.450000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/6bd580bb-4765-4193-82f7-410ece3c1773" />&nbsp;<img alt="page15image65270336" width="230.090000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/65592418-e6fe-4181-97d1-ea386cccc23a" /><img alt="page15image65266496" width="230.450000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1b07e05e-c97e-428b-84ad-f0225a3a6386" />&nbsp;<img alt="page15image65264960" width="230.090000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/28eabe43-7bd2-4616-b611-633b9c12028a" /></p><p>Investigations</p><p>Very common: Common:</p><p>Very common:</p><p>Pyrexia, fatigue<br />Acute phase reaction, pain</p><p>Hypocalcaemia</p><p>Common:<br />1Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid as indicated in sections 4.1 and 4.2 (see section 4.8)</p><p>In paediatric patients with severe osteogenesis imperfecta, zoledronic acid seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.</p><p>After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.</p><p>Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t1&frasl;2&nbsp;&nbsp;0.24 and t1&frasl;2&beta;&nbsp;1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t1&frasl;2&gamma;&nbsp;146 hours. There was no accumulation of zoledronic acid in plasma after multiple doses given every 28 days. Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue.</p><p>From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease</p><p>Hypophosphataemia</p><p><img alt="page15image65266688" width="230.450000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/a6b66ad9-b4b0-4af0-b5d3-ba53bc8873a3" />&nbsp;<img alt="page15image65266304" width="230.810000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d3b4d957-8834-4aba-aee4-9eb5c54857dd" /></p><p>15</p><p>in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.</p><p>The interpatient variability in pharmacokinetic parameters for zoledronic acid was high, as seen with other bisphosphonates.</p><p>No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency. Zoledronic acid does not inhibit human P450 enzymes&nbsp;in vitro, shows no biotransformation and in animal studies &lt; 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.</p><p>The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 &plusmn; 33% of the creatinine clearance, which showed a mean of 84 &plusmn; 29 ml/min (range<br />22 to 143 ml/min) in the 64 cancer patients studied. Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min. Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance &lt; 30 ml/min).</p><p>In an&nbsp;in vitro&nbsp;study, zoledronic acid showed low affinity for the cellular components of human blood, with a mean blood to plasma concentration ratio of 0.59 in a concentration range of 30 ng/ml to<br />5000 ng/ml. The plasma protein binding is low, with the unbound fraction ranging from 60% at<br />2 ng/ml to 77% at 2000 ng/ml of zoledronic acid.</p><p>Special populations</p><p>Paediatric patients</p><p>Limited pharmacokinetic data in children with severe osteogenesis imperfecta suggest that zoledronic acid pharmacokinetics in children aged 3 to 17 years are similar to those in adults at a similar mg/kg dose level. Age, body weight, gender and creatinine clearance appear to have no effect on zoledronic acid systemic exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute toxicity<br />The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in rats.</p><p>Subchronic and chronic toxicity<br />Zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2-3 days in dogs for up to 52 weeks was also well tolerated.</p><p>The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the&nbsp;compound&rsquo;s pharmacological antiresorptive activity.</p><p>The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose. Longer-term repeat administration at doses bracketing the highest intended human therapeutic dose of zoledronic acid produced toxicological effects in other organs, including the gastrointestinal tract, liver, spleen and lungs, and at intravenous injection sites.</p><p>&nbsp;</p><p>Reproduction toxicity<br />Zoledronic acid was teratogenic in the rat at subcutaneous doses&nbsp;&ge;&nbsp;0.2 mg/kg. Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found. Dystocia was observed at the lowest dose (0.01 mg/kg bodyweight) tested in the rat.</p><p>Mutagenicity and carcinogenic potential<br />Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Sodium citrate Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To avoid potential incompatibilities, Acidoxax4 mg/5 ml concentrate for solution for infusion is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution.</p><p>This medicinal product must not be mixed with calcium or other divalent cation-containing infusion&nbsp;solutions such as lactated Ringer&rsquo;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

After dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C and at 25°C after dilution in 100 ml 0.9% w/v sodium chloride solution or 100 ml 5% w/v glucose. From a microbiological point of view, the solution for infusion should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C.

If refrigerated, the solution must be allowed to reach room temperature before administration.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>For storage conditions of Acidoxaxafter dilution, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml concentrate in a plastic vial made of clear, colourless oleofinic polymer closed with fluoropolymer-coated bromobutyl rubber stopper and aluminium cap with plastic flip-off component.</p><p>Acidoxax4 mg/5 ml concentrate for solution for infusion is supplied as packs containing 1, 4 or 10 vials.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Prior to administration, 5 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution).</p><p>Additional information on handling of Zoledronic acid Actavis, including guidance on preparation of reduced doses, is provided in section 4.2.</p><p>Aseptic techniques must be followed during the preparation of the infusion. For single use only. Only clear solution free from particles and discolouration should be used.</p><p>Healthcare professionals are advised not to dispose of unused Acidoxaxvia the domestic sewage system.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical company Olaya st
Riyadh, Saudia Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>